NFJ Investment Group LLC Takes $2.77 Million Position in ANI Pharmaceuticals, Inc. $ANIP

NFJ Investment Group LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 33,409 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,766,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares during the last quarter. Jane Street Group LLC bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $2,706,000. Finally, Norges Bank bought a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $625,000. Institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Stephen P. Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the sale, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. The trade was a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president directly owned 74,424 shares in the company, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 18,987 shares of company stock worth $1,546,405. Insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ANIP. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Canaccord Genuity Group dropped their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Trading Down 0.9%

NASDAQ ANIP opened at $77.32 on Friday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $70.15 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a 50 day simple moving average of $80.48 and a two-hundred day simple moving average of $78.91. The stock has a market cap of $1.78 billion, a P/E ratio of 16.66 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period last year, the company earned $1.80 EPS. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.